FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid…
MB-106 clinical trial under Mustang’s IND continues to enroll patients Additional IND filing and published research expected in 2023 across…
-Reduced TGF-β2, but not TGF-β1 nor TGF-β3, is associated with improved OS. AGOURA HILLS, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE)…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical…
-- Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in…
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and…
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory…
With nearly four years of study follow-up, all-oral, fixed-duration IMBRUVICA® (ibrutinib) + venetoclax reduced the risk of progression or death…
FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into…
NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced…